Abstract

Two dialysis patients developed recurrent restless legs syndrome. The clinical courses and the association between the α1-microglobulin removal rate and the therapeutic effects of hemodiafiltration were analyzed. Case 1: a middle-aged woman was switched from predilution online hemodiafiltration to hemodialysis, following which the α1-microglobulin removal rate decreased from 39.1 to 29.9%. A month later, the severe restless legs syndrome occurred. The treatment was then switched to high-efficiency hemodiafiltration and 2 weeks later, these symptoms were resolved. The α1-microglobulin removal rate increased to 41.9%. Her symptoms recurred 5 years later with severity; thus, the hemodiafiltration treatment conditions were changed. Under revised conditions, the α1-microglobulin removal rate was 42.6%, and her symptoms were alleviated. Continuation of high-efficiency hemodiafiltration led to the resolution of the syndrome at 1 month after recurrence. Case 2: a middle-aged man on hemodialysis developed the restless legs syndrome in the second year of treatment. The α1-microglobulin removal rate was 23.8%. After switching to a month-long high-efficiency hemodiafiltration with a removal rate of ≥ 40%, his symptoms were resolved. However, the syndrome recurred after a year with severity. The symptoms were alleviated using various measures. The hemodiafilters were changed, and hemodiafiltration with an α1-microglobulin removal rate of ≥ 40% was continued; 2 months later, his symptoms resolved. High-efficiency online hemodiafiltration is an effective therapeutic strategy for restless legs syndrome in dialysis patients. We found, for the first time, that target removal efficiency is an α1-microglobulin removal rate of 40% or higher.

Highlights

  • Restless legs syndrome (RLS) is mainly divided into primary and secondary RLS

  • We previously reported that the RLS symptoms in dialysis patients improved through the use of online hemodiafiltration (OL-HDF), which increased the removal efficiency of the low molecular weight proteins (LMWP) [3]

  • We aimed to describe the clinical course of two patients with recurrent RLS and investigate the therapeutic effect of high-efficiency OL-HDF

Read more

Summary

Introduction

Restless legs syndrome (RLS) is mainly divided into primary (idiopathic) and secondary (symptomatic) RLS. The development of primary RLS has not been fully elucidated; a dopaminergic neuron hypofunction, the relationship between iron metabolism and dopamine, and genetic predisposition are considered as risk factors for RLS. The incidence rate is high in pregnant women, patients with iron deficiency anemia, patients with diabetes mellitus and patients with end stage renal disease [1, 2]. The causative substances of RLS in dialysis patients have not been elucidated yet, and no detailed investigation has been performed

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call